Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yukihiro Ohno

Showing results (1-10 of 79) with videos related to

Pageof 8
Sort By:
CNS Neuroscience & Therapeutics|November 25, 2010
Therapeutic role of 5-HT1A receptors in the treatment of schizophrenia and Parkinson's diseaseYukihiro Ohno
Neural Regeneration Research|May 4, 2018
Astrocytic Kir4.1 potassium channels as a novel therapeutic target for epilepsy and mood disordersYukihiro Ohno
Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica|August 15, 2008
[Spatial potassium buffering]Yukihiro Ohno
Central Nervous System Agents in Medicinal Chemistry|June 4, 2010
New insight into the therapeutic role of 5-HT1A receptors in central nervous system disordersYukihiro Ohno
CNS & Neurological Disorders Drug Targets|April 11, 2017
Therapeutic Role of Synaptic Vesicle Glycoprotein 2A (SV2A) in Modulating EpileptogenesisYukihiro Ohno, Kentaro Tokudome
Aging and Disease|February 21, 2013
Improving the Treatment of Parkinson's Disease: A Novel Approach by Modulating 5-HT(1A) ReceptorsSaki Shimizu, Yukihiro Ohno
Journal of Pharmacological Sciences|December 28, 2020
Perisynaptic astrocytes as a potential target for novel antidepressant drugsMarcos E Frizzo, Yukihiro Ohno
Journal of Pharmacological Sciences|April 9, 2009
Effects of tandospirone, a 5-HT1A agonistic anxiolytic agent, on haloperidol-induced catalepsy and forebrain Fos expression in miceYukihiro Ohno, Saki Shimizu, Junta Imaki
CNS & Neurological Disorders Drug Targets|July 13, 2013
Improving the treatment of schizophrenia: role of 5-HT receptors in modulating cognitive and extrapyramidal motor functionsSaki Shimizu, Yuto Mizuguchi, Yukihiro Ohno
Japanese Journal of Pharmacology|August 20, 2002
7-Hydroxy-N,N'-di-n-propyl-2-aminotetraline, a preferential dopamine D3 agonist, induces c-fos mRNA expression in the rat cerebellumTadashi Ishibashi, Junko Wakabayashi, Yukihiro Ohno
Pageof 8

Showing results (1-10 of 79) with videos related to

Sort By:
Pageof 8
CNS Neuroscience & Therapeutics|November 25, 2010
Therapeutic role of 5-HT1A receptors in the treatment of schizophrenia and Parkinson's diseaseYukihiro Ohno
Neural Regeneration Research|May 4, 2018
Astrocytic Kir4.1 potassium channels as a novel therapeutic target for epilepsy and mood disordersYukihiro Ohno
Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica|August 15, 2008
[Spatial potassium buffering]Yukihiro Ohno
Central Nervous System Agents in Medicinal Chemistry|June 4, 2010
New insight into the therapeutic role of 5-HT1A receptors in central nervous system disordersYukihiro Ohno
CNS & Neurological Disorders Drug Targets|April 11, 2017
Therapeutic Role of Synaptic Vesicle Glycoprotein 2A (SV2A) in Modulating EpileptogenesisYukihiro Ohno, Kentaro Tokudome
Aging and Disease|February 21, 2013
Improving the Treatment of Parkinson's Disease: A Novel Approach by Modulating 5-HT(1A) ReceptorsSaki Shimizu, Yukihiro Ohno
Journal of Pharmacological Sciences|December 28, 2020
Perisynaptic astrocytes as a potential target for novel antidepressant drugsMarcos E Frizzo, Yukihiro Ohno
Journal of Pharmacological Sciences|April 9, 2009
Effects of tandospirone, a 5-HT1A agonistic anxiolytic agent, on haloperidol-induced catalepsy and forebrain Fos expression in miceYukihiro Ohno, Saki Shimizu, Junta Imaki
CNS & Neurological Disorders Drug Targets|July 13, 2013
Improving the treatment of schizophrenia: role of 5-HT receptors in modulating cognitive and extrapyramidal motor functionsSaki Shimizu, Yuto Mizuguchi, Yukihiro Ohno
Japanese Journal of Pharmacology|August 20, 2002
7-Hydroxy-N,N'-di-n-propyl-2-aminotetraline, a preferential dopamine D3 agonist, induces c-fos mRNA expression in the rat cerebellumTadashi Ishibashi, Junko Wakabayashi, Yukihiro Ohno
Pageof 8